Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High - What's Next?

Key Points

• Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares reached a new 52-week high of $29.58, reflecting increased investor interest with a trading volume of over 1.6 million shares.
• The stock has a consensus buy rating from analysts, with a target price averaging $43.14, despite a recent downgrade to "hold" by some firms.
• Recent insider trading included the sale of 15,000 shares by insider James C. Hamilton at an average price of $25.00, decreasing their overall ownership by 5.72%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares reached a new 52-week high on Thursday . The stock traded as high as $29.55 and last traded at $29.58, with a volume of 1638708 shares. The stock had previously closed at $28.89.

Wall Street Analyst Weigh In

ARWR has been the topic of several research reports. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Royal Bank Of Canada lowered their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Finally, B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

The company has a market cap of $4.11 billion, a P/E ratio of -23.22 and a beta of 1.00. The company's 50-day moving average is $19.48 and its two-hundred day moving average is $16.41. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the prior year, the firm posted ($1.38) EPS. Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 25,000 shares of company stock worth $575,000 in the last three months. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares during the period. Virtus Advisers LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. Nisa Investment Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 1,308 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $49,000. Finally, CWM LLC boosted its position in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 2,523 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.